Upsized $300M biotech IPO could be huge — or another flop in Alzheimer’s and ALS

There's a lot riding on Denali Therapeutics Inc.'s upsized, mountainous $303 million IPO — and it goes beyond the eye-popping fundraise. To be sure, investors are watching the South San Francisco developer of drugs for Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, or ALS — in a Securities and Exchange Commission filing Thursday morning, the 125-employe e company boosted the shares available in the IPO from 9.58 million to 15.97 million. At the top of its $17 to…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news